Literature DB >> 28429128

Endophthalmitis associated with Purpureocillium lilacinum during infliximab treatment for surgically induced necrotizing scleritis, successfully treated with 27-gauge vitrectomy.

Masaaki Yoshida1, Shunji Yokokura2, Hiroshi Kunikata1,3, Naoko Takada1, Kazuichi Maruyama1, Masahiro Toyokawa4, Kazushi Kashio4, Mitsuo Kaku5, Toru Nakazawa1,3,6,7.   

Abstract

PURPOSE: To report a case of endophthalmitis associated with Purpureocillium lilacinum (P. lilacinum) during infliximab treatment for surgically induced necrotizing scleritis, successfully treated with 27-gauge vitrectomy.
METHODS: A single case report.
RESULTS: A 71-year-old man who had undergone immunosuppressive therapy, including infliximab, for surgically induced necrotizing scleritis (SINS) in his left eye complained of visual disturbance and eye pain in the eye. He had a past history of surgery for recurrent pterygium: pterygium excision, amnion transplantation with mitomycin C and limbal transplantation. Visual acuity in the left eye was counting fingers at 30 cm, and intraocular pressure was 3.0 mmHg. Slit-lamp examination revealed the presence of anterior chamber cells (3+), and a B-mode ultrasound scan showed a vitreous opacity. We made a diagnosis of endophthalmitis and performed 27-gauge microincision vitrectomy surgery (27GMIVS) with antibiotic perfusion of ceftazidime, vancomycin and voriconazole. Intraoperative findings included a fungus-like ball-shaped opacity in the vitreous, and a close-to-normal retinal appearance. A vitreous body culture identified the presence of P. lilacinum. After 2 months of antibacterial and antifungal therapy, inflammation decreased and visual acuity recovered to 20/100.
CONCLUSIONS: This is the first report of a case of endophthalmitis associated with P. lilacinum during infliximab treatment for SINS. Scleral thinning due to necrotizing scleritis, especially during immunosuppressive therapy, is a risk factor for endophthalmitis. We found that 27GMIVS was a useful strategy for such a challenging clinical situation.

Entities:  

Keywords:  27-Gauge microincision vitrectomy surgery; Endophthalmitis; Infliximab; Necrotizing scleritis; Purpureocillium lilacinum

Mesh:

Substances:

Year:  2017        PMID: 28429128     DOI: 10.1007/s10792-017-0532-4

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  19 in total

1.  Purpureocillium, a new genus for the medically important Paecilomyces lilacinus.

Authors:  Jennifer Luangsa-Ard; Jos Houbraken; Tineke van Doorn; Seung-Beom Hong; Andrew M Borman; Nigel L Hywel-Jones; Robert A Samson
Journal:  FEMS Microbiol Lett       Date:  2011-06-23       Impact factor: 2.742

Review 2.  Infections due to emerging and uncommon medically important fungal pathogens.

Authors:  T J Walsh; A Groll; J Hiemenz; R Fleming; E Roilides; E Anaissie
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

3.  Multicenter study of infliximab for refractory uveoretinitis in Behçet disease.

Authors:  Annabelle A Okada; Hiroshi Goto; Shigeaki Ohno; Manabu Mochizuki
Journal:  Arch Ophthalmol       Date:  2012-05

4.  Multicenter survey with a systematic overview of acute-onset endophthalmitis after transconjunctival microincision vitrectomy surgery.

Authors:  Yusuke Oshima; Kazuaki Kadonosono; Hidetaka Yamaji; Makoto Inoue; Munenori Yoshida; Hideya Kimura; Masahito Ohji; Fumio Shiraga; Toshimitsu Hamasaki
Journal:  Am J Ophthalmol       Date:  2010-08-16       Impact factor: 5.258

5.  Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.

Authors:  Grace Levy-Clarke; Douglas A Jabs; Russell W Read; James T Rosenbaum; Albert Vitale; Russell N Van Gelder
Journal:  Ophthalmology       Date:  2013-12-17       Impact factor: 12.079

6.  Outcomes of 27 Gauge Microincision Vitrectomy Surgery for Posterior Segment Disease.

Authors:  M Ali Khan; Abtin Shahlaee; Brian Toussaint; Jason Hsu; Arunan Sivalingam; Pravin U Dugel; Rohit R Lakhanpal; Christopher D Riemann; Maria H Berrocal; Carl D Regillo; Allen C Ho
Journal:  Am J Ophthalmol       Date:  2015-09-28       Impact factor: 5.258

Review 7.  Infections associated with tumor necrosis factor-alpha antagonists.

Authors:  David J Rychly; Joseph T DiPiro
Journal:  Pharmacotherapy       Date:  2005-09       Impact factor: 4.705

Review 8.  Current perspectives on ophthalmic mycoses.

Authors:  Philip A Thomas
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

9.  Topical voriconazole therapy of Purpureocillium lilacinum keratitis that occurred in disposable soft contact lens wearers.

Authors:  Daisuke Todokoro; Norihiro Yamada; Mariko Fukuchi; Shoji Kishi
Journal:  Int Ophthalmol       Date:  2014-06-29       Impact factor: 2.031

10.  Retrospective case-series of Paecilomyces lilacinus ocular mycoses in Queensland, Australia.

Authors:  Liam Daniel Turner; Diana Conrad
Journal:  BMC Res Notes       Date:  2015-10-31
View more
  4 in total

Review 1.  Identifying and Treating Ocular Manifestations in Psoriasis.

Authors:  Mahsaw Motlagh; Christopher Fortenbach; Howard I Maibach; Bobeck S Modjtahedi
Journal:  Am J Clin Dermatol       Date:  2021-11-03       Impact factor: 7.403

Review 2.  Human Pathogenic Paecilomyces from Food.

Authors:  Danielly C Moreira; Manoel M E Oliveira; Cintia M Borba
Journal:  Microorganisms       Date:  2018-07-05

Review 3.  Ocular side effects of antirheumatic medications: a qualitative review.

Authors:  Clara M Castillejo Becerra; Yue Ding; Beatrice Kenol; Andrew Hendershot; Alexa Simon Meara
Journal:  BMJ Open Ophthalmol       Date:  2020-01-07

Review 4.  A review of ocular adverse events of biological anti-TNF drugs.

Authors:  Fernanda Nicolela Susanna; Carlos Pavesio
Journal:  J Ophthalmic Inflamm Infect       Date:  2020-04-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.